A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies
Pneumonia, Pneumocystis Carinii, HIV Infections
About this trial
This is an interventional treatment trial for Pneumonia, Pneumocystis Carinii focused on measuring Trimetrexate, Pneumonia, Pneumocystis carinii, Quinazolines, Infusions, Intravenous, Injections, Intravenous, Leucovorin, Drug Evaluation, Drug Therapy, Combination, Administration, Oral, Acquired Immunodeficiency Syndrome, Antiprotozoal Agents, AIDS-Related Complex
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Blood pressure medication. Concurrent Treatment: Allowed: Blood products. Ventilatory support. Patients must have the following: Diagnosis of Pneumocystis carinii pneumonia (PCP). Be HIV positive by ELISA, HIV culture, or p24 antigenemia; or be a member of an identified risk group. Intolerant to trimethoprim / sulfamethoxazole (TMP / SMX). Intolerant to pentamidine. Prior Medication: Allowed: Trimethoprim / sulfamethoxazole trials. Pentamidine trials. Myelosuppressive agents. Nephrotoxic agents. Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients who do not meet the inclusion criteria are excluded. Concurrent Medication: Excluded: Myelosuppressive agents. Nephrotoxic agents. Other investigational drugs including high-dose steroids (exceeding physiologic replacement doses). Patients who do not meet the inclusion criteria are excluded.
Sites / Locations
- Warner-Lambert Parke-Davis